236 related articles for article (PubMed ID: 25134670)
21. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.
Naji M; Zhao C; Welsh SJ; Meades R; Win Z; Ferrarese A; Tan T; Rubello D; Al-Nahhas A
Mol Imaging Biol; 2011 Aug; 13(4):769-75. PubMed ID: 20700766
[TBL] [Abstract][Full Text] [Related]
23. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
24. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
25. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
26. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.
Afshar-Oromieh A; Giesel FL; Linhart HG; Haberkorn U; Haufe S; Combs SE; Podlesek D; Eisenhut M; Kratochwil C
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1409-15. PubMed ID: 22669255
[TBL] [Abstract][Full Text] [Related]
27. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
28. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
[TBL] [Abstract][Full Text] [Related]
30. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.
Koopmans KP; Jager PL; Kema IP; Kerstens MN; Albers F; Dullaart RP
J Nucl Med; 2008 Aug; 49(8):1232-7. PubMed ID: 18632829
[TBL] [Abstract][Full Text] [Related]
31. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.
Froeling V; Elgeti F; Maurer MH; Scheurig-Muenkler C; Beck A; Kroencke TJ; Pape UF; Hamm B; Brenner W; Schreiter NF
Ann Nucl Med; 2012 Nov; 26(9):738-43. PubMed ID: 22865406
[TBL] [Abstract][Full Text] [Related]
32. A rare case of a
Kroiss AS; Uprimny C; Pichler R; Gasser RW; Virgolini IJ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(5):315-317. PubMed ID: 30042056
[TBL] [Abstract][Full Text] [Related]
33. Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.
Venkitaraman B; Karunanithi S; Kumar A; Khilnani GC; Kumar R
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):856-64. PubMed ID: 24435773
[TBL] [Abstract][Full Text] [Related]
34. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME; Schuetz M; Magnaldi S; Weber M; Trattnig S; Karanikas G
Eur Radiol; 2012 Apr; 22(4):938-46. PubMed ID: 22080251
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
36. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of (68)Ga-DOTANOC PET/CT imaging in pheochromocytoma.
Sharma P; Dhull VS; Arora S; Gupta P; Kumar R; Durgapal P; Malhotra A; Chumber S; Ammini AC; Kumar R; Bal C
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):494-504. PubMed ID: 24158184
[TBL] [Abstract][Full Text] [Related]
38. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
Schartinger VH; Dudás J; Decristoforo C; Url C; Schnabl J; Göbel G; Virgolini IJ; Riechelmann H; Rasse M; Waitz D; Putzer D
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1365-72. PubMed ID: 23685751
[TBL] [Abstract][Full Text] [Related]
39. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
40. Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas.
Nyuyki F; Plotkin M; Graf R; Michel R; Steffen I; Denecke T; Geworski L; Fahdt D; Brenner W; Wurm R
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):310-8. PubMed ID: 19763565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]